Billionaire Stanley Druckenmiller’s New AI Warning and Top 10 Stock Picks

Page 1 of 3

Billionaire Stanley Druckenmiller’s latest stock portfolio is out, but it’s his explosive new prediction about artificial intelligence that is sending shockwaves through Wall Street.

Druckenmiller Says He’s “Not Playing” in the Stock Market

In a recent interview with Morgan Stanley’s Iliana Bouzali, the legendary investor revealed that he had become unusually cautious about the stock market. After nearly 50 years of investing, Druckenmiller said he could barely remember a time when he had so little clarity about where markets were heading over the next 12 months.

“I’m not playing,” he said, explaining that his firm had largely stepped back from making major directional bets.

Druckenmiller said his net equity exposure was roughly flat, with both long and short positions. “We’re trying to not lose money as opposed to make money,” he said. We also covered his new healthcare picks.

His Big AI Prediction: Selling Tasks Instead of Tokens

Druckenmiller believes the next major AI investment opportunity may shift away from infrastructure, including chips and data centers, toward companies that use AI to perform actual business tasks.

He said that beaten-down AI infrastructure stocks could offer tactical opportunities but questioned whether the sector would deliver the same extraordinary investment gains as in previous years.

His bigger prediction concerns leading AI laboratories. Instead of primarily selling access to their models through tokens, companies developing the world’s most powerful AI systems could begin selling completed services directly to customers.

That means businesses could pay AI providers to complete software development, cybersecurity investigations, and other complex tasks rather than purchasing model access and building their own solutions.

Why Cybersecurity Stocks Could Face a Serious Threat

Druckenmiller specifically singled out cybersecurity as an industry potentially vulnerable to this shift.

“Who’s going to compete with these guys in cybersecurity?” he asked.

He said that leading AI laboratories could deploy swarms of intelligent agents capable of defending businesses against increasingly sophisticated cyberattacks.

Such a development could threaten established cybersecurity companies if AI providers begin competing directly for their customers. However, Druckenmiller did not identify individual cybersecurity stocks to sell.

Methodology

For this article, we reviewed Stanley Druckenmiller’s Duquesne Family Office’s third-quarter 2026 13F holdings, as reported to the Securities and Exchange Commission. We selected the firm’s 10 largest non-option holdings based on their reported market values as of September 30, 2026, and ranked them in ascending order of stake value, from the smallest at number 10 to the largest at number one. The list includes both individual stocks and exchange-traded funds, while excluding separately reported call and put options. We also examined changes in the number of shares held during the quarter to determine whether Duquesne increased or reduced each position. His earlier picks are in our list of the best non-AI stocks he owns.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 612% since May 2014, beating its benchmark by 375 percentage points (see more details here).

You can see the top 5 stocks in this list in our video by clicking the image below:

#10 Revolution Medicines, Inc. (NASDAQ:RVMD)

Duquesne Family Office Stake: $89.55 Million

Revolution Medicines develops cancer drugs, and its first approved one, RASONQUE, treats pancreatic cancer. More than 5,000 patients received it in the first five weeks, and health plans covering over 90% of US pancreatic cancer lives have reimbursed claims. Most patients had other treatments first, so earlier use can add sales.

The stock trades at about 57 times forward sales, while the median healthcare stock trades at about 3.5 times. Early sales included one-time boosts from patients moving over from the Expanded Access Program, which will fade. Costs and net loss rose from a year earlier. Revolution Medicines has little room for a slow launch.

Stanley Druckenmiller’s Duquesne Family Office increased its stake in Revolution Medicines by approximately 10% during the third quarter of 2026. According to its latest 13F filing, the firm held 436,287 shares worth approximately $89.55 million as of September 30, accounting for 2.00% of its reported portfolio. Click to read our earlier take on this biotech pick.

#9 Insmed Incorporated (NASDAQ:INSM)

Duquesne Family Office Stake: $124.72 Million

Duquesne Family Office reduced its Insmed shareholding by approximately 23% during the third quarter of 2026. At the end of September, the firm owned 1,092,650 common shares worth approximately $124.72 million, representing 2.79% of its reported portfolio. This excludes a separately reported call-option position in Insmed.

Insmed Incorporated makes lung disease drugs, and its pill BRINSUPRI is the only approved medicine for non-cystic fibrosis bronchiectasis. Management raised its 2026 BRINSUPRI sales guidance twice. An FDA decision in January 2027 could widen who can use its older drug ARIKAYCE, and the pipeline drug TPIP is in Phase 3 trials for high blood pressure in the lungs.

BRINSUPRI made up 76.3% of third quarter sales, so the company depends on one drug. Boehringer Ingelheim has a rival pill that works the same way in Phase 3, and AstraZeneca collects royalties that rise as sales grow. Research costs for TPIP keep climbing. Insmed Incorporated needs BRINSUPRI to keep growing fast to cover them. See our take on this healthcare stock.

#8 iShares MSCI Brazil ETF (NYSEARCA:EWZ)

Duquesne Family Office Stake: $125.81 Million

The iShares MSCI Brazil ETF is an exchange-traded fund designed to track the performance of large- and mid-capitalization Brazilian equities. It provides exposure to major Brazilian companies across sectors such as financial services, energy, materials, and consumer businesses.

Duquesne Family Office decreased its position in the iShares MSCI Brazil ETF by approximately 2% during the third quarter. The firm reported ownership of 3,377,570 ETF shares worth approximately $125.81 million at the end of September 2026. The holding represented 2.81% of its reported portfolio.

Page 1 of 3